The insider selling at around the current share price of US$80.90 is a cause for slight concern. The lack of insider purchases in the last year, despite significant insider ownership, does not inspire confidence in the company.
Efficient markets hypothesis implies markets are over-reactive and investors may not always be rational. The firm's higher EPS growth versus its annual share price increment indicates a potential surge in market caution towards the stock.
Insider trading at Pinnacle Financial Partners suggests a bearish signal as there's been more selling than buying in the past year. While strong insider ownership is seen as positive, extensive share selling warrants closer inspection.
Upgrades •$Allegiance(ABTX.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $43 •$邦吉(BG.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130) •$Cerence(CRNC.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28) •$First Mid Bancshares(FMBH.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $45 •$拉馬爾戶外廣告(LAMR.US)$: Citigroup Up...
Gainers: •$Checkmate Pharmaceuticals(CMPI.US)$+331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash) •$Axsome Therapeutics(AXSM.US)$+27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder) •$超微電腦(SMCI.US)$+14.3% (earnings report) •$普拉格能源(PLUG.US)$+9.24% (t...
Pinnacle Financial Partners股票討論區
• $Allegiance(ABTX.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $邦吉(BG.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence(CRNC.US)$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares(FMBH.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $拉馬爾戶外廣告(LAMR.US)$ : Citigroup Up...
• $Checkmate Pharmaceuticals(CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics(AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $超微電腦(SMCI.US)$ +14.3% (earnings report)
• $普拉格能源(PLUG.US)$ +9.24% (t...
finally close at all time high
暫無評論